{
  "id": "63f043e4f36125a426000023",
  "type": "yesno",
  "question": "Is Baricitinib effective for Alopecia Areata?",
  "ideal_answer": "Yes. In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35334197",
    "http://www.ncbi.nlm.nih.gov/pubmed/35330989"
  ],
  "snippets": [
    {
      "text": "Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35330989",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35330989",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two Phase 3 Trials of Baricitinib for Alopecia Areata.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334197",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: In two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334197",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}